share_log

Invivyd | UPLOAD: Others

SEC announcement ·  Feb 24 03:09
Summary by Futu AI
Invivyd, Inc., a biotechnology company, has been informed by the United States Securities and Exchange Commission (SEC) that its Registration Statement on Form S-3, filed on February 9, 2024, will not undergo review by the commission. The SEC's communication, dated February 23, 2024, and addressed to Invivyd's CEO David Hering, explicitly states that the company should not expect a review and reminds them of their responsibility for the accuracy and adequacy of their disclosures. The SEC also referenced Rules 460 and 461, which pertain to requests for acceleration of the registration process. Invivyd and its management have been directed to contact Lauren Hamill for any further inquiries regarding the matter.
Invivyd, Inc., a biotechnology company, has been informed by the United States Securities and Exchange Commission (SEC) that its Registration Statement on Form S-3, filed on February 9, 2024, will not undergo review by the commission. The SEC's communication, dated February 23, 2024, and addressed to Invivyd's CEO David Hering, explicitly states that the company should not expect a review and reminds them of their responsibility for the accuracy and adequacy of their disclosures. The SEC also referenced Rules 460 and 461, which pertain to requests for acceleration of the registration process. Invivyd and its management have been directed to contact Lauren Hamill for any further inquiries regarding the matter.

The information provided by Futu AI is automatically generated by third-party artificial intelligence (AI) software based on news content. It is only available to users located outside of China mainland.


The above content is for informational or educational purposes only and does not constitute any investment advice related to Futu. Although we strive to ensure the truthfulness, accuracy, and originality of all such content, we cannot guarantee it.